ArticleMolecular pharmaceutics
Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers.
Article in Molecular pharmaceutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Nanoparticle-Enabled Modulation of the Bone Immune Microenvironment for Enhanced Regeneration.Bioengineering (Basel, Switzerland) · 2026Review
- Beyond bisphosphonates: radiolabeled phosphopeptides for bone targeting.EJNMMI research · 2026Article
- Unveiling innovative therapeutic strategies and future trajectories on stimuli-responsive drug delivery systems for targeted treatment of breast carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Advances in Bone-Targeting Drug Delivery: Emerging Strategies Using Adeno-Associated Virus.Human gene therapy · 2024Review
- Targeting Intratibial Osteosarcoma Using Water-Soluble Copolymers Conjugated to Collagen Hybridizing Peptides.Molecular pharmaceutics · 2023Article
- Real-World Methotrexate Dose on Clinical Effectiveness and Structural Damage of Certolizumab Pegol With Rheumatoid Arthritis.Frontiers in medicine · 2021Article
- Bone-Targeting Systems to Systemically Deliver Therapeutics to Bone Fractures for Accelerated Healing.Current osteoporosis reports · 2020Review
- Polymer nanomedicines.Advanced drug delivery reviews · 2020Review
- Biomaterial-assisted local and systemic delivery of bioactive agents for bone repair.Acta biomaterialia · 2019Review
- Multivalent Presentation of Peptide Targeting Groups Alters Polymer Biodistribution to Target Tissues.Biomacromolecules · 2018Article
- Small non-coding RNAs-based bone regulation and targeting therapeutic strategies.Molecular and cellular endocrinology · 2017Review
- Pharmacokinetic and Biodistribution Studies of HPMA Copolymer Conjugates in an Aseptic Implant Loosening Mouse Model.Molecular pharmaceutics · 2017Article
- Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate.Journal of controlled release : official journal of the Controlled Release Society · 2016Article
- Bone site-specific delivery of siRNA.Journal of biomedical research · 2016Review
- Biodistribution of Fracture-Targeted GSK3β Inhibitor-Loaded Micelles for Improved Fracture Healing.Biomacromolecules · 2015Article
- Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer.Scientific reports · 2015Article
- Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature.Current drug targets · 2015Review
- Prevention of alveolar bone loss in an osteoporotic animal model via interference of semaphorin 4d.Journal of dental research · 2014Article
- Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats.Biomaterials · 2013Article
- Polymer-drug conjugates: origins, progress to date and future directions.Advanced drug delivery reviews · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Osteotropicity of novel bone-targeted HPMA copolymer conjugates has been demonstrated previously with bone histomorphometric analysis. The pharmacokinetics and biodistribution of this delivery system were investigated in the current study with healthy young BALB/c mice. The 125I-labeled bone-targeted and control (nontargeted) HPMA copolymers were administered intravenously to mice, and their distribution to different organs and tissues was followed using gamma counter and single photon emission computed tomography (SPECT). Both the invasive and noninvasive data further confirmed that the incorporation of D-aspartic acid octapeptide (D-Asp8) as bone-targeting moiety could favorably deposit the HPMA copolymers to the entire skeleton, especially to the high bone turnover sites. To evaluate the influence of molecular weight, three fractions (Mw of 24, 46, and 96 kDa) of HPMA copolymer-D-Asp8 conjugate were prepared and evaluated. Higher molecular weight of the conjugate enhanced the deposition to bone due to the prolonged half-life in circulation, but it weakened the bone selectivity. A higher content of bone-targeting moiety (D-Asp8) in the conjugate is desirable to achieve superior hard tissue selectivity. Further validation of the bone-targeting efficacy of the conjugates in animal models of osteoporosis and other skeletal diseases is needed in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.